{"id":66037,"date":"2026-01-13T06:50:39","date_gmt":"2026-01-13T01:20:39","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=66037"},"modified":"2026-01-13T06:50:41","modified_gmt":"2026-01-13T01:20:41","slug":"what-is-the-current-approval-status-of-mavacamten","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/","title":{"rendered":"What is the current approval status of Mavacamten?"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/t66F8kQMVms?si=xouwge8-Eywe1TUU\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">As of early 2026, <strong>Mavacamten<\/strong> is a fully approved, first-in-class cardiac myosin inhibitor. It is widely authorized for use in over 50 countries across five continents. Its current regulatory and clinical status is summarized below:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. Primary Approved Indication<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Mavacamten is approved for the treatment of <strong>adults with symptomatic New York Heart Association (NYHA) class II-III hypertrophic <strong>obstructive <\/strong>cardiomyopathy (HOCM)<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Goal:<\/strong> To improve functional capacity, reduce left ventricular outflow tract (LVOT) obstruction, and alleviate symptoms like shortness of breath and fatigue.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Major Regulatory Milestones<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>United States (FDA):<\/strong> Originally approved in April 2022. As of April 2025, the FDA updated the label to <strong>reduce echocardiography monitoring requirements<\/strong>, making the treatment slightly less burdensome for patients while maintaining safety.<\/li>\n\n\n\n<li class=\"\"><strong>European Union (EMA):<\/strong> Approved in mid-2023. It remains an authorized therapy across the EU for adult HOCM.<\/li>\n\n\n\n<li class=\"\"><strong>Global Reach:<\/strong> It has received approvals in major markets including Canada, Australia, Brazil, Switzerland, and China.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Recent Developments (January 2026)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Adolescent Use:<\/strong> On January 12, 2026, <strong><a href=\"https:\/\/news.bms.com\/news\/corporate-financial\/2026\/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-SCOUT-HCM-Trial-Evaluating-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM\/default.aspx\">positive Phase 3 results<\/a><\/strong> from the <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038603\/\"><strong>SCOUT-HCM<\/strong> trial<\/a> has been announced. This study showed that mavacamten significantly reduced LVOT obstruction in <strong>adolescents (ages 12 to &lt;18)<\/strong>. While not yet fully approved for this age group, these results support an upcoming regulatory filing to expand the indication to younger patients.<\/li>\n\n\n\n<li class=\"\"><strong>Market Competition:<\/strong> As of January 2026, mavacamten is no longer the only drug in its class. A second cardiac myosin inhibitor, <strong><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2401424\">Aficamten<\/a><\/strong>, received <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition\">FDA approval<\/a> in late December 2025, providing a new alternative for HOCM patients.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">4. Safety and Monitoring (REMS)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Because Mavacamten works by reducing heart muscle contraction, it carries a risk of heart failure if the left ventricular ejection fraction (LVEF) drops too low.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>REMS Program:<\/strong> In the U.S., it is only available through the <strong>REMS<\/strong> (Risk Evaluation and Mitigation Strategy) program.<\/li>\n\n\n\n<li class=\"\"><strong>Monitoring:<\/strong> Patients must undergo regular echocardiograms to monitor heart function and ensure the dosage is safe.<\/li>\n\n\n\n<li class=\"\"><strong>Drug Interactions:<\/strong> Monitoring for interactions with CYP2C19 and CYP3A4 inhibitors\/inducers is critical, as these can significantly affect the drug&#8217;s levels in the blood. CYP2C19: Cytochrome P450 family 2 subfamily C member 19. CYP2C19: Cytochrome P450 family 3 subfamily A member 4.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>As of early 2026, Mavacamten is a fully approved, first-in-class cardiac myosin inhibitor. It is widely authorized for use in over 50 countries across five continents. Its current regulatory and clinical status is summarized below: 1. Primary Approved Indication Mavacamten is approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":66042,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-66037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"As of early 2026, Mavacamten is a fully approved, first-in-class cardiac myosin inhibitor. It is widely authorized for use in over 50 countries across five continents. Its current regulatory and clinical status is summarized below: 1. Primary Approved Indication Mavacamten is approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T01:20:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T01:20:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"676\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"What is the current approval status of Mavacamten?\",\"datePublished\":\"2026-01-13T01:20:39+00:00\",\"dateModified\":\"2026-01-13T01:20:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/\"},\"wordCount\":348,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Mavacamten-for-HOCM-2026-Update.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/\",\"name\":\"What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Mavacamten-for-HOCM-2026-Update.jpg\",\"datePublished\":\"2026-01-13T01:20:39+00:00\",\"dateModified\":\"2026-01-13T01:20:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Mavacamten-for-HOCM-2026-Update.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Mavacamten-for-HOCM-2026-Update.jpg\",\"width\":1200,\"height\":676},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/what-is-the-current-approval-status-of-mavacamten\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What is the current approval status of Mavacamten?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/","og_locale":"en_US","og_type":"article","og_title":"What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders","og_description":"As of early 2026, Mavacamten is a fully approved, first-in-class cardiac myosin inhibitor. It is widely authorized for use in over 50 countries across five continents. Its current regulatory and clinical status is summarized below: 1. Primary Approved Indication Mavacamten is approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-01-13T01:20:39+00:00","article_modified_time":"2026-01-13T01:20:41+00:00","og_image":[{"width":1200,"height":676,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"What is the current approval status of Mavacamten?","datePublished":"2026-01-13T01:20:39+00:00","dateModified":"2026-01-13T01:20:41+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/"},"wordCount":348,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/","url":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/","name":"What is the current approval status of Mavacamten? - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg","datePublished":"2026-01-13T01:20:39+00:00","dateModified":"2026-01-13T01:20:41+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/Mavacamten-for-HOCM-2026-Update.jpg","width":1200,"height":676},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/what-is-the-current-approval-status-of-mavacamten\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"What is the current approval status of Mavacamten?"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=66037"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66037\/revisions"}],"predecessor-version":[{"id":66043,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66037\/revisions\/66043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/66042"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=66037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=66037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=66037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}